AUTHORS
Melinda Tan, MD, Christoph Schaefers, MD2, Kenneth JC Lim, MBBS3, Darin Carabenciov4, Katharine Dooley, MPH5, Soren Kaster6, Nadine Abdallah I, MD7, Saurabh Chhabra, MD, MBBS8, Ricardo Daniel Parrondo, MD9, Morie Gertz, MD10, Taxiarchis Kourelis, MD11, Rahma Warsame, MD12, Joselle M Cook, M.D.13, Moritz Binder, MD, MPH14, Andre De Menezes Silva Corraes, MD15, Malvika Gupta, MD16, Udit Yadav, MBBS17, P. Leif Bergsagel, MD18, J Erin Wiedmeier-Nutor, MD,MPH19, Saurabh Zanwar, MBBS, MD20, Rafael Fonseca, MD21, Prashant Kapoor, MD22, Sikander Ailawadhi, MD23, Shaji Kumar, MD24, Anastasia Zekeridou, MD25, Yi Lin Jr, MD, PhD26
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Phoenix, Arizona, United States
9 Mayo Clinic, Jacksonville, Florida, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Phoenix, Arizona, United States
18 Mayo Clinic, Phoenix, Arizona, United States
19 Mayo Clinic, Phoenix, Arizona, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Phoenix, Arizona, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Jacksonville, Florida, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States
26 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Delayed neurotoxicity (DNT), including immune effector cell-associated parkinsonism (PKS) and cranial nerve palsies (CNP), occurs in 10-15% of patients treated with ciltacabtagene autoleucel (cilta-cel). Among patients with high post-infusion lymphocyte expansion (absolute lymphocyte count peak [ALCpeak ≥3×10?/L; ALChi) DNT incidence increases to 25-30%, yet effective preventive strategies are lacking. Following our previous observation that prophylactic dexamethasone (PPX DEX) failed to reduce the incidence of DNT, we prospectively evaluated prophylactic cyclophosphamide (PPX CTX) as a mitigation strategy and its associated immune mechanisms.
We conducted a single-arm prospective, observation study (one-sided α=0.10, 90% power) evaluating whether a single 500 mg dose of CTX administered at ALChi reduced DNT incidence by 90%. Outcomes were compared with predefined cohorts receiving no prophylaxis (historical cohort [HIS]) or PPX DEX (10 mg twice daily for ≥3 days). Endpoints included DNT incidence, event-free survival (EFS), and ALC kinetics. Peripheral blood (PB) and bone marrow (BM) immune composition were assessed by multiparameter flow cytometry. Single-cell RNA sequencing (sc-RNAseq) (T cells=228093) was performed on paired BM and PB samples collected at pre-lymphodepletion (pre-LD), peak CAR T-cell expansion (PK), and month 1 (M1) post-infusion from patients with PKS (n=2) and without neurotoxicity (no-tox; n=1).
Among 126 patients treated within the PPX CTX cohort, 55 had ALChi and received prophylactic CTX. Patients in the HIS cohort were younger than PPX DEX and PPX CTX cohorts (p=0.02), but cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, disease burden measured by involved free light chains, and bone marrow plasma cell before lymphodepletion were comparable across all three ALChi cohorts.
PPX CTX did not reduce the incidence of DNT or PKS in ALChi pts compared with HIS or PPX DEX cohorts (DNT/PKS: PPX CTX 20%/9%, HIS 22%/9%, PPX DEX 23%/8%; all p=NS), and DNT-free and PKS-free EFS were similar across cohorts. Although the incidence of PKS was unchanged, neurological manifestations appeared less severe following PPX CTX, with four of five affected patients experiencing mild symptoms and two demonstrating clinical improvement or resolution after corticosteroids with or without intravenous immunoglobulin.
PPX CTX did not significantly modify post-infusion lymphocyte kinetics, including ALC expansion, post-peak contraction, or cumulative lymphocyte exposure (AUC), compared with PPX DEX. No significant differences in CD4/CD8 T-cell distribution were observed at Day 14, Month 1, or Month 3.
Flow cytometry demonstrated CD4-predominant T-cell expansion (CD4/CD8 >1) in patients who developed DNT. Pts with CD4 predominance was numerically higher in PKS than CNP at pre-LD (100% vs 67%, p=0.12), and month 1 (63% vs 52%, p=0.45), although differences were not statistically significant.
Compared to the case with no toxicity, PKS cases had more activated CD4 Th2 T cells in the BM and PB at pre-LD and persistent elevated percentage of CAR positive (CARpos) and CAR negative (CARneg) activated CD4 Th2 T cells at M1. PKS cases also had more CARneg CD8 Tscm (stem central memory) at PK, and tissue recirculating CARpos and CARneg CD8 CTL (cytotoxic T cells) at M1; whereas the case with no toxicity had more senescent CD8 CTL in the BM and PB at pre-LD, senescent and terminally exhausted CD8 CTL at peak and M1, with the exhausted CD8 CTL being predominantly CARneg at M1.
Administration of prophylactic CTX following high lymphocyte expansion post-infusion was feasible and safe but did not alter lymphocyte kinetics or reduce DNT incidence after cilta-cel. Translational immune profiling suggest that PKS is associated with expansion of distinct CAR-positive CD8 and CD4 T cell subsets. These findings suggest that preventing delayed neurotoxicity will require refinement of risk-adapted prophylactic strategies, including more effective modulation of high-risk immune expansion and selective targeting of pathogenic immune cell subsets.
DISCLOSURES
Melinda Tan, MD: No relevant conflicts of interest to declare.